aztreonam has been researched along with Cronobacter Infections in 38 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aztreonam was administered to 30 patients, ages 0." | 5.27 | Aztreonam in the treatment of severe urinary tract infections in pediatric patients. ( Assael, BM; Boccazzi, A; Colombo, R; Crossignani, RM; Garlaschi, L; Rancilio, L; Rusconi, F, 1986) |
| "Treatment with vancomycin and aztreonam was associated with a rapid quantitative reduction in faecal colonisation with enterobacteriaceae, whereas there was no quantitative reduction in colonisation with enterobacteriaceae associated with treatment with vancomycin and gentamicin." | 2.67 | Enterobacteriaceae and neonatal necrotising enterocolitis. ( Langdale, V; Levene, M; MacKay, P; Martin, C; Millar, MR, 1992) |
| "The antimicrobial efficacy of meropenem (MEM), cefepime (FEP), and aztreonam (ATM), each in combination with NAC, were assessed in vitro and in vivo against Klebsiella pneumoniae and Escherichia coli." | 1.62 | Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection ( Asai, N; Hagihara, M; Kato, H; Koizumi, Y; Mikamo, H; Okade, H; Sakanashi, D; Sato, N; Shibata, Y; Suematsu, H; Sugano, T; Yamagishi, Y, 2021) |
| " However, in the light of dose-limiting hepatotoxicity of aztreonam, short half life of avibactam, significant protein binding of aztreonam, appropriate dosing and method of administration to optimize PK/PD and toxicodynamics for this combination is being debated." | 1.62 | Management of serious infections caused by metallo β-lactamases with or without OXA-48-like expressing Enterobacterales with aztreonam and ceftazidime/avibactam combination: Dosing strategy for better clinical outcome. ( Bakthavatchalam, YD; Manesh, A; Nagvekar, V; Nangia, V; Soman, R; Swaminathan, S; Veeraraghavan, B, 2021) |
| "Checkerboard experiments followed by fractional inhibitory concentration (FIC) index determinations are commonly used to assess in vitro pharmacodynamic interactions between combined antibiotics, but FIC index cannot be determined in case of antibiotic/non-active compound combinations." | 1.51 | Pharmacodynamic modelling of β-lactam/β-lactamase inhibitor checkerboard data: illustration with aztreonam-avibactam. ( Buyck, J; Chauzy, A; Couet, W; de Jonge, BLM; Grégoire, N; Marchand, S, 2019) |
| " Pharmacokinetic (PK)/pharmacodynamic (PD) understanding of this combination is critical for optimal clinical dose selection." | 1.42 | Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. ( Bradford, PA; Eakin, AE; Harris, JJ; Kim, A; McLaughlin, RE; O'Donnell, JP; Patey, S; Singh, R; Tanudra, MA, 2015) |
| " A humanized aztreonam dose of 2 g every 6 h (1-h infusion) was evaluated alone and in combination with avibactam at 375 or 600 mg every 6 h (1-h infusion), targeting the percentage of the dosing interval in which free-drug concentrations remained above the MIC (fT>MIC)." | 1.39 | Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. ( Crandon, JL; Nicolau, DP, 2013) |
| "Cellulitis is usually caused by organisms such as beta-hemolytic streptococci and Staphylococcus aureus." | 1.32 | Sepsis in a renal transplant recipient due to Citrobacter braakii. ( Agraharkar, ML; Gupta, R; Rauf, SJ; Singh, S; Smith, J, 2003) |
| "aeruginosa burn wound infection, aztreonam and piperacillin should be considered as the first line of defense." | 1.30 | The use of aztreonam as an alternate therapy for multi-resistant Pseudomonas aeruginosa. ( Heggers, JP; Herndon, DN; Villarreal, C; Walton, MA, 1997) |
| "Tigemonam proved to be a bactericidal antibiotic." | 1.28 | In vitro activity of tigemonam against multiresistant nosocomial Enterobacteriaceae. ( Avlamis, A; Giamarellou, H; Grammatikou, M; Papoulias, G; Pephanis, A, 1989) |
| "Aztreonam was used for a year to treat 106 hospitalized patients with a total of 131 documented gram-negative infections." | 1.27 | Treatment of serious gram-negative infections with aztreonam. ( Bollinger, M; Darji, TB; Greenberg, RN; Luppen, KL; McMillian, R; Noorani, AA; Reilly, PM; Wolk, SM, 1984) |
| "Aztreonam was administered to 30 patients, ages 0." | 1.27 | Aztreonam in the treatment of severe urinary tract infections in pediatric patients. ( Assael, BM; Boccazzi, A; Colombo, R; Crossignani, RM; Garlaschi, L; Rancilio, L; Rusconi, F, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (23.68) | 18.7374 |
| 1990's | 5 (13.16) | 18.2507 |
| 2000's | 7 (18.42) | 29.6817 |
| 2010's | 13 (34.21) | 24.3611 |
| 2020's | 4 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, L | 1 |
| Zhen, S | 1 |
| Shen, Y | 1 |
| Zhang, T | 1 |
| Wang, J | 2 |
| Li, J | 1 |
| Lin, Q | 1 |
| Xiao, Z | 1 |
| Zheng, Y | 1 |
| Jiang, E | 1 |
| Han, M | 1 |
| Feng, S | 1 |
| Cairns, KA | 1 |
| Hall, V | 1 |
| Martin, GE | 1 |
| Griffin, DWJ | 1 |
| Stewart, JD | 1 |
| Khan, SF | 1 |
| Abbott, IJ | 1 |
| Meher-Homji, Z | 1 |
| Morrissey, CO | 1 |
| Sia, C | 1 |
| Love, J | 1 |
| Corallo, CE | 1 |
| Bergin, P | 1 |
| Sharma, A | 1 |
| Basu, G | 1 |
| Spencer, A | 1 |
| Peleg, AY | 1 |
| Hagihara, M | 1 |
| Kato, H | 1 |
| Sugano, T | 1 |
| Okade, H | 1 |
| Sato, N | 1 |
| Shibata, Y | 1 |
| Sakanashi, D | 1 |
| Asai, N | 1 |
| Koizumi, Y | 1 |
| Suematsu, H | 1 |
| Yamagishi, Y | 1 |
| Mikamo, H | 1 |
| Veeraraghavan, B | 1 |
| Bakthavatchalam, YD | 1 |
| Soman, R | 1 |
| Swaminathan, S | 1 |
| Manesh, A | 1 |
| Nagvekar, V | 1 |
| Nangia, V | 1 |
| Ansari, M | 1 |
| Munir, T | 1 |
| Saad, N | 1 |
| Chew, KL | 1 |
| Tay, MKL | 1 |
| Cheng, B | 1 |
| Lin, RTP | 1 |
| Octavia, S | 1 |
| Teo, JWP | 1 |
| Avery, LM | 1 |
| Nicolau, DP | 2 |
| Hobson, CA | 1 |
| Bonacorsi, S | 1 |
| Fahd, M | 1 |
| Baruchel, A | 1 |
| Cointe, A | 1 |
| Poey, N | 1 |
| Jacquier, H | 1 |
| Doit, C | 1 |
| Monjault, A | 1 |
| Tenaillon, O | 1 |
| Birgy, A | 1 |
| Chauzy, A | 1 |
| Buyck, J | 1 |
| de Jonge, BLM | 1 |
| Marchand, S | 1 |
| Grégoire, N | 1 |
| Couet, W | 1 |
| Crandon, JL | 1 |
| Hickman, RA | 1 |
| Hughes, D | 1 |
| Cars, T | 1 |
| Malmberg, C | 1 |
| Cars, O | 1 |
| Singh, R | 1 |
| Kim, A | 1 |
| Tanudra, MA | 1 |
| Harris, JJ | 1 |
| McLaughlin, RE | 2 |
| Patey, S | 1 |
| O'Donnell, JP | 1 |
| Bradford, PA | 2 |
| Eakin, AE | 1 |
| Campos, JC | 1 |
| da Silva, MJ | 1 |
| dos Santos, PR | 1 |
| Barros, EM | 1 |
| Pereira, Mde O | 1 |
| Seco, BM | 1 |
| Magagnin, CM | 1 |
| Leiroz, LK | 1 |
| de Oliveira, TG | 1 |
| de Faria-Júnior, C | 1 |
| Cerdeira, LT | 1 |
| Barth, AL | 1 |
| Sampaio, SC | 1 |
| Zavascki, AP | 1 |
| Poirel, L | 1 |
| Sampaio, JL | 1 |
| Dupont, H | 1 |
| Gaillot, O | 1 |
| Goetgheluck, AS | 1 |
| Plassart, C | 1 |
| Emond, JP | 1 |
| Lecuru, M | 1 |
| Gaillard, N | 1 |
| Derdouri, S | 1 |
| Lemaire, B | 1 |
| Girard de Courtilles, M | 1 |
| Cattoir, V | 1 |
| Mammeri, H | 1 |
| Kazmierczak, KM | 1 |
| Rabine, S | 1 |
| Hackel, M | 1 |
| Biedenbach, DJ | 1 |
| Bouchillon, SK | 1 |
| Sahm, DF | 1 |
| Mischnik, A | 1 |
| Baumert, P | 1 |
| Hamprecht, A | 1 |
| Rohde, A | 1 |
| Peter, S | 1 |
| Feihl, S | 1 |
| Knobloch, J | 1 |
| Gölz, H | 1 |
| Kola, A | 1 |
| Obermann, B | 1 |
| Querbach, C | 1 |
| Willmann, M | 1 |
| Gebhardt, F | 1 |
| Tacconelli, E | 1 |
| Gastmeier, P | 1 |
| Seifert, H | 1 |
| Kern, WV | 1 |
| Sy, S | 1 |
| Zhuang, L | 1 |
| Xia, H | 1 |
| Beaudoin, ME | 1 |
| Schuck, VJ | 1 |
| Derendorf, H | 1 |
| Liu, G | 1 |
| Ling, BD | 1 |
| Zeng, Y | 1 |
| Lin, L | 1 |
| Xie, YE | 1 |
| Lei, J | 1 |
| Mazzariol, A | 1 |
| Zuliani, J | 1 |
| Fontana, R | 1 |
| Cornaglia, G | 1 |
| Gupta, R | 1 |
| Rauf, SJ | 1 |
| Singh, S | 1 |
| Smith, J | 1 |
| Agraharkar, ML | 1 |
| Berezin, AG | 1 |
| Romashov, OM | 1 |
| Iakovlev, SV | 1 |
| Sidorenko, SV | 1 |
| Nijssen, S | 1 |
| Florijn, A | 1 |
| Bonten, MJ | 1 |
| Schmitz, FJ | 1 |
| Verhoef, J | 1 |
| Fluit, AC | 1 |
| Jaber, A | 1 |
| Nong, M | 1 |
| Thiagarajan, P | 1 |
| Greenberg, RN | 1 |
| Reilly, PM | 1 |
| Luppen, KL | 1 |
| McMillian, R | 1 |
| Bollinger, M | 1 |
| Wolk, SM | 1 |
| Darji, TB | 1 |
| Noorani, AA | 1 |
| Kobasa, WD | 1 |
| Kaye, D | 1 |
| Bonner, DP | 1 |
| Whitney, RR | 1 |
| Baughn, CO | 1 |
| Miller, BH | 1 |
| Olsen, SJ | 1 |
| Sykes, RB | 1 |
| Turcotte, A | 1 |
| Simard, M | 1 |
| Morin, NJ | 1 |
| Beauchamp, D | 1 |
| Bergeron, MG | 1 |
| Walton, MA | 1 |
| Villarreal, C | 1 |
| Herndon, DN | 1 |
| Heggers, JP | 1 |
| Kuga, A | 1 |
| Okamoto, R | 1 |
| Inoue, M | 1 |
| Iakovlev, VP | 1 |
| Fayed, DF | 1 |
| Dahmash, NS | 1 |
| Saddique, AA | 1 |
| Shibl, AM | 1 |
| Millar, MR | 1 |
| MacKay, P | 1 |
| Levene, M | 1 |
| Langdale, V | 1 |
| Martin, C | 1 |
| Allen, KD | 1 |
| Green, HT | 1 |
| Hechler, U | 1 |
| van den Weghe, M | 1 |
| Martin, HH | 1 |
| Frère, JM | 1 |
| Giamarellou, H | 1 |
| Pephanis, A | 1 |
| Grammatikou, M | 1 |
| Avlamis, A | 1 |
| Papoulias, G | 1 |
| Rusconi, F | 1 |
| Assael, BM | 1 |
| Boccazzi, A | 1 |
| Colombo, R | 1 |
| Crossignani, RM | 1 |
| Garlaschi, L | 1 |
| Rancilio, L | 1 |
| Lagast, H | 1 |
| Klastersky, J | 1 |
| Kains, JP | 1 |
| van der Auwera, P | 1 |
| Meunier, F | 1 |
| Woussen, F | 1 |
| Thijs, JP | 1 |
| Bremner, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) Combined With Infusions of ex Vivo Regulatory T Cells Depleted T Lymphocytes in in Vivo Regulatory T Cells Depleted Patients as [NCT01513109] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2011-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for aztreonam and Cronobacter Infections
| Article | Year |
|---|---|
[Characteristics and clinical value of extended-spectrum beta-lactamases].
Topics: Adolescent; Adult; Aged; Animals; Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; beta-Lac | 2003 |
[Aztreonam].
Topics: Aztreonam; Drug Evaluation; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; In Vitro Tech | 1992 |
3 trials available for aztreonam and Cronobacter Infections
| Article | Year |
|---|---|
Evaluation of aztreonam in the treatment of serious gram-negative infections in a university hospital in Saudi Arabia.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Aztreonam; Bacteremia; Citrobacter; Cross Infection; | 1992 |
Enterobacteriaceae and neonatal necrotising enterocolitis.
Topics: Aztreonam; Drug Therapy, Combination; England; Enterobacteriaceae Infections; Enterocolitis, Pseudom | 1992 |
Empiric antimicrobial therapy with aztreonam or ceftazidime in gram-negative septicemia.
Topics: Adult; Aged; Aztreonam; Blood Bactericidal Activity; Ceftazidime; Enterobacteriaceae Infections; Fem | 1986 |
33 other studies available for aztreonam and Cronobacter Infections
| Article | Year |
|---|---|
Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options.
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenem-Resistant Enterobacteriaceae; Ceftazidime; Drug Combina | 2023 |
Treatment of invasive IMP-4 Enterobacter cloacae infection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases; Ceftazi | 2021 |
Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases | 2021 |
Management of serious infections caused by metallo β-lactamases with or without OXA-48-like expressing Enterobacterales with aztreonam and ceftazidime/avibactam combination: Dosing strategy for better clinical outcome.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamases; Ceftazidime; Drug Combinati | 2021 |
Phenotypic Identification, Frequency Distribution and Antibiogram of Carbapenemase Producing Enterobacteriaceae in Clinical Isolates.
Topics: Amoxicillin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ca | 2018 |
Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases; Carbape | 2018 |
Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; | 2018 |
Successful Treatment of Bacteremia Due to NDM-1-Producing
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacteremia; beta-Lactamases; Ceftazidime; Ce | 2019 |
Pharmacodynamic modelling of β-lactam/β-lactamase inhibitor checkerboard data: illustration with aztreonam-avibactam.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; Carbapenem-Resist | 2019 |
Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases | 2013 |
Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
Topics: Amdinocillin; Anti-Bacterial Agents; Aztreonam; Cell Wall; Drug Resistance, Multiple, Bacterial; Dru | 2014 |
Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lac | 2015 |
Characterization of Tn3000, a Transposon Responsible for blaNDM-1 Dissemination among Enterobacteriaceae in Brazil, Nepal, Morocco, and India.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; Base Sequence; beta-Lactamases; Brazil; Conjug | 2015 |
Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Outer Membrane Proteins; beta-Lact | 2016 |
Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.
Topics: Aztreonam; beta-Lactam Resistance; beta-Lactamases; Enterobacteriaceae; Enterobacteriaceae Infection | 2016 |
Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; | 2017 |
Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; Drug Res | 2017 |
Molecular characterization of extended-spectrum beta-lactamases produced by clinical isolates of Enterobacter cloacae from a Teaching Hospital in China.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; China; Co | 2008 |
Isolation from blood culture of a Leclercia adecarboxylata strain producing an SHV-12 extended-spectrum beta-lactamase.
Topics: Acute Disease; Anti-Bacterial Agents; Aztreonam; Bacteremia; beta-Lactam Resistance; beta-Lactamases | 2003 |
Sepsis in a renal transplant recipient due to Citrobacter braakii.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Bacteremia; Cellulitis; Citrobacter freundi | 2003 |
Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates.
Topics: Aztreonam; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cephalo | 2004 |
Transient neutrophilic thrombophagocytosis associated with Citrobacter freundii septicemia.
Topics: Aged; Anti-Bacterial Agents; Aztreonam; Citrobacter freundii; Enterobacteriaceae Infections; Humans; | 2006 |
Treatment of serious gram-negative infections with aztreonam.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Drug Evaluation; En | 1984 |
Aztreonam, cefoperazone, and gentamicin in the treatment of experimental Enterobacter aerogenes endocarditis in rabbits.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Cefoperazone; Endocarditis, Bacterial; Enterobacter; Ente | 1983 |
In-vivo properties of SQ 26,776.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Enterobacteriaceae Infections; Haemophilus influenzae; La | 1981 |
Differential distributions in tissues and efficacies of aztreonam and ceftazidime and in vivo bacterial morphological changes following treatment.
Topics: Animals; Aztreonam; Ceftazidime; Cephalosporins; Enterobacter cloacae; Enterobacteriaceae Infections | 1997 |
The use of aztreonam as an alternate therapy for multi-resistant Pseudomonas aeruginosa.
Topics: Aminoglycosides; Aztreonam; Burns; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Thera | 1997 |
ampR gene mutations that greatly increase class C beta-lactamase activity in Enterobacter cloacae.
Topics: Amino Acid Sequence; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Ceftazi | 2000 |
Aztreonam in infections due to aerobic gram-negative bacteria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aztreonam; Enterobacteriaceae; Enterobacteriaceae Infect | 1989 |
Overproduced beta-lactamase and the outer-membrane barrier as resistance factors in Serratia marcescens highly resistant to beta-lactamase-stable beta-lactam antibiotics.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Ce | 1989 |
In vitro activity of tigemonam against multiresistant nosocomial Enterobacteriaceae.
Topics: Aztreonam; Ceftriaxone; Cross Infection; Drug Resistance, Microbial; Enterobacteriaceae Infections; | 1989 |
Aztreonam in the treatment of severe urinary tract infections in pediatric patients.
Topics: Adolescent; Aztreonam; Child; Child, Preschool; Citrobacter; Enterobacter; Enterobacteriaceae Infect | 1986 |
In-vitro activity of the monobactam Ro 17-2301 against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; Enterobacteriaceae; Enterobacteriaceae Infections; Gentamicins; Hu | 1985 |